AMAaron W. Miller

Aaron W. Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aaron W. Miller has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Voluntary wheel running modulates murine gut microbiome during hyperammonemic stress

    by Annette Bellar, Naseer Sangwan, Aaron Miller, Avinash Kumar, Thomas Jaramillo, Saurabh Mishra, Pugazhendhi Kannan, Amy Attaway, Lopa Mishra, Nicole Welch, et al.

    Exercise modulates multiple physiological systems, including skeletal muscle and the gut microbiome (GMB). Ammonia, a microbiome-derived cytotoxic metabolite, causes cellular hyperammonemic stress (HAS) in chronic diseases. We investigated the impact of voluntary wheel running (VWR) on GMB during HAS in a mouse model. Male C57BL/6J mice were randomized to treatment with either ammonium acetate (AmAc) (2.5 mmol/kg/day) or vehicle for 6 weeks. Stool 16S rRNA sequencing was performed at baseline, pre-intervention, and post-intervention. GMB diversity, taxa-level abundance, and correlation analyses were performed. Overall GMB composition remained stable between baseline and pre-intervention across groups ( r > 0.57; P < 0.001). Following interventions, VWR or usual activity (UA), alpha-diversity was highest in AmAc-treated, specifically AmAc-VWR, mice. Eubacterium xylanophilum was reduced in AmAc-UA vs other groups ( P < 0.05). Akkermansia abundance declined over time in UA mice, but in AmAc-VWR mice, this depletion was reversed ( P = 0.002). Clostridium sensu stricto 1 and Eubacterium ventriosum were increased in AmAc-VWR mice ( P < 0.05). Correlation analysis revealed high stability in PBS-UA ( r = 0.667; P < 0.001), moderate restructuring in AmAc-VWR ( r = 0.566; P < 0.001), and PBS-VWR ( r = 0.385; P = 0.0099). HAS-induced GMB instability, with loss of beneficial taxa, including short-chain fatty acid-producing bacteria, was partially ameliorated by VWR. Exercise-mediated GMB modulation may be a strategy to mitigate HAS-induced complications in chronic diseases. IMPORTANCE: Voluntary exercise is recommended in chronic diseases to improve outcomes, but biological responses in disease are not well characterized. Perturbations in the metabolism of ammonia, a microbiome-generated toxin, occur in chronic diseases that can be compounded by muscle-generated ammonia during exercise. Exercise-induced molecular responses are adversely affected by hyperammonemic stress of chronic diseases, including liver cirrhosis. We investigated gut microbiome changes during voluntary wheel running, which replicates human endurance exercise in a preclinical mouse model of hyperammonemia. Adverse impacts of Hyperammonemic stress included a reduction in short-chain fatty acid producers that were reversed by voluntary wheel running. Our data lay the foundation for future studies on how endurance-type exercise promotes a favorable gut microbial composition and strategies to use exercise as a regulator of hyperammonemic stress via targeting the gut microbiome.


  • Top Cited Papers
    Open Access

    Proteomic Profiles of Seminal Plasma in Individuals with Secondary Infertility: Insights into the Involvement of Oxidative Stress

    by Raneen Sawaid Kaiyal, Sromona D. Mukherjee, Manesh Kumar Panner Selvam, Aaron W. Miller, Sarah C. Vij, Scott D. Lundy

    Background/Objectives: Male infertility, including primary and secondary infertility, is significantly influenced by oxidative stress, which disrupts sperm function and fertility. Seminal plasma, a protein-rich fluid essential for sperm protection and function, represents a valuable source for identifying biomarkers through proteomic analysis. While previous studies have explored seminal plasma proteins in fertility, the specific proteomic changes associated with oxidative stress in secondary infertility remain unclear. This study aimed to characterize these alterations by analyzing seminal plasma from three groups: men with secondary infertility, fertile donors with high oxidative stress, and fertile donors without oxidative stress. Methods: Pooled semen samples from each group underwent quantitative proteomics analysis using advanced mass spectrometry, with subsequent bioinformatic analysis using tools like DAVID, STRING, and IPA for identifying differentially expressed proteins (DEPs). Results: Quantitative proteomic analysis identified 377 DEPs in secondary infertility and 523 DEPs in fertile donors with high oxidative stress compared to controls. Bioinformatic analysis revealed seven shared pathways, including acute-phase response signaling, organismal injury, cellular movement, cell-to-cell signaling, free radical scavenging, immune cell trafficking, and Hematological system development. Notably, C3 and SERPINA3 exhibited significant alterations, along with proteins involved in sperm motility, capacitation, and fertilization, suggesting their potential roles in impaired fertility. Conclusions: These findings underscore the link between oxidative stress and secondary infertility and highlight specific seminal plasma proteins as potential biomarkers and therapeutic targets for diagnosing and treating male infertility.


  • Top Cited Papers
    Open Access

    Predicting probiotic success: lessons from Oxalobacter and oxalate metabolism

    by Mangesh Suryavanshi, Sromona D. Mukherjee, Aaron W. Miller

    The gut microbiota influences host metabolism, immunity, and organ physiology, making it an attractive therapeutic target. However, clinical probiotic trials often produce inconsistent results, reflecting context-dependent effects shaped by metabolic, ecological, dietary, and host-specific factors. We critically synthesized the literature on hyperoxaluria, a condition of elevated urinary oxalate associated with kidney stones and chronic kidney disease, as a mechanistically tractable model for probiotic development. We examined evidence from clinical studies, microbiome analyses, and mechanistic experiments to identify factors influencing efficacy, with a focus on Oxalobacter formigenes, a specialist oxalate-degrading anaerobe. Across trials, probiotic success depended less on dose, strain identity, or persistence, and more on the ecological context - particularly the baseline abundance of oxalate-degrading genes (oxc, frc) in the native microbiota. Efficacy was highest when these metabolic niches were vacant. Diet, delivery format, and broader microbial community structure also shaped outcomes. A taxon-centric approach is insufficient for predicting probiotic efficacy. We propose a three-phase framework for rational design: (1) case–control microbiome studies to identify metabolically relevant deficits; (2) mechanistic in vivo and in vitro validation to establish causality; and (3) complex systems modeling to predict context-specific responses. This metabolism-first, ecology-grounded strategy is generalizable to other microbiota-linked conditions and supports precision microbial therapeutics.


  • Open Access

    Evaluating the use of biobanked urine specimens for human urobiome studies

    by Sromona D. Mukherjee, Ava Adler, Thien Dang, Eric N. Taylor, Gary Curhan, Aaron W. Miller

    Case–control studies focused on the urinary tract microbiome, or urobiome, have consistently reported significant associations with disease. However, clinical urobiome studies have typically been small, averaging ~50 patients per study. While these sample sizes are sufficient to detect large effect sizes, they have not been able to differentiate disease phenotypes within a larger disease complex (e.g., different types of kidney stones), which have unique etiological origins. Biobanked urine specimens can help fill this void. However, since these specimens were not collected specifically for urobiome studies, they must be validated before drawing any strong conclusions. The objective of this study was to evaluate microbiome data derived from metagenomic analysis of biobanked urine specimens against the following criteria: (i) level of contaminants; (ii) retention of high-quality DNA; (iii) overgrowth of a few dominant bacteria; and (iv) preservation of sex-specific taxa. A total of 174 samples were assessed from biobanked or freshly collected specimens ( N = 118 patients total), in addition to multiple positive and negative controls. While there were significant differences in diversity (alpha/beta; P < 0.001) based on whether or not samples were biobanked, these differences can largely be explained by study-specific variation. With these criteria, we find that biobanked urine specimens provide similar data to fresh specimens collected using standardized protocols and can be used for clinical urobiome studies. IMPORTANCE: The urinary tract microbiome, or urobiome, is an emerging field of study that has shown promise as an important contributor to urologic health and disease. However, since this field is relatively new, clinical studies to evaluate the urobiome in the context of urologic disease have been relatively small. The use of biobanked urine specimens would allow for much larger studies to be conducted in a relatively short period of time. However, the use of biobanked urine specimens must first be validated. In this study, we sought to evaluate the use of biobanked urine specimens through multiple metrics, compared to previous studies conducted specifically to assess the impact of the urobiome. Results of our study suggest that biobanked urine specimens produce similar data to urine samples collected under rigorously controlled conditions and can be used in casecontrol studies of urologic conditions.


  • Open Access

    Baseline abundance of oxalate-degrading bacteria determines response to Oxalobacter formigenes probiotic therapy

    by Mangesh Suryavanshi, Arthur Franklin, Sonia Fargue, Dean G. Assimos, John Knight, Aaron W. Miller

    Oxalate, a compound derived from both diet and metabolism, contributes to multiple renal and vascular diseases. Certain gut bacteria degrade oxalate, limiting absorption and promoting secretion. This study examined microbial factors that influence the effectiveness of Oxalobacter formigenes, a specialized oxalate-degrading bacterium, in lowering urinary oxalate levels. We analyzed gut microbiota from a controlled diet study involving 26 healthy, non-stone-forming adults who were initially uncolonized and then colonized with O. formigenes. Stool samples were profiled for 16S rRNA and oxalate-degrading genes-oxalyl-CoA decarboxylase (oxc) and formyl-CoA transferase (frc)-using high-throughput amplicon sequencing and qPCR. Comparative analyses assessed associations between microbial features and oxalate homeostasis, including changes in urinary oxalate excretion. The baseline abundance of oxalate-degrading genes (oxc and frc) was significantly and negatively correlated with stool oxalate (R = -0.43 for frc, -0.34 for oxc), urinary oxalate levels (R = -0.25 for frc, -0.27 for oxc), and the reduction in urine oxalate after O. formigenes administration (R = -0.36 for frc, -0.42 for oxc). This study provides the first direct evidence that baseline oxalate-degrading gene abundance predicts probiotic response. Results explain inconsistent clinical trial results and support precision microbiome-based therapy for hyperoxaluria via targeted patient stratification.


  • Open Access

    Impact of study design, contamination, and data characteristics on results and interpretation of microbiome studies

    by Jose Agudelo, Aaron W. Miller

    Advances in high-throughput molecular techniques have enabled microbiome studies in low-biomass environments, which pose unique challenges due to contamination risks. While best-practice guidelines can reduce contamination by over 90%, the impact of residual contamination and data set variability on statistical outcomes remains understudied. Here, we quantitatively assessed how study design factors influence microbiome analyses using simulated and real-world data sets. Alpha diversity was affected by sample number and community dissimilarity, but not by the number of unique taxa. Beta diversity was influenced primarily by unique taxa and group dissimilarity, with a marginal effect of sample number. The number of differentially abundant taxa depended on the number of unique taxa but was also influenced by sample number, depending on thealgorithm. Notably, contamination had a marginal impact on weighted beta diversity but altered the number of differentially abundant taxa when at least 10 contaminants were present, with a greater effect as contamination increased. Findings closely mirrored results from seven real-world low-biomass data sets. Overall, group dissimilarity and the number of unique taxa were the primary drivers of statistical outcomes. The DESeq2 algorithm outperformed ANCOM-BC when exposed to stochastically distributed contamination, but algorithms were equivocal under contamination weighted toward one group. In all cases, the rate of false positives in differential abundance analyses was <15%. Importantly, in both simulated and real-world data, contamination rarely impacts whether microbiome differences were detected but did affect the number of differentially abundant taxa. Thus, when validated protocols with internal negative controls are used, residual contamination minimally impacts statistical outcomes. Alpha diversity was affected by sample number and community dissimilarity, but not by the number of unique taxa. Beta diversity was influenced primarily by unique taxa and group dissimilarity, with a marginal effect of sample number. The number of differentially abundant taxa depended on the number of unique taxa but was also influenced by sample number, depending on the algorithm. Notably, contamination had a marginal impact on weighted beta diversity but altered the number of differentially abundant taxa when at least 10 contaminants were present, with a greater effect as contamination increased. Findings closely mirrored results from seven real-world low-biomass data sets. Overall, group dissimilarity and the number of unique taxa were the primary drivers of statistical outcomes. The DESeq2 algorithm outperformed ANCOM-BC when exposed to stochastically distributed contamination, but algorithms were equivocal under contamination weighted toward one group. In all cases, the rate of false positives in differential abundance analyses was <15%. Importantly, in both simulated and real-world data, contamination rarely whether microbiome differences were detected but did affect the number of differentially abundant taxa. Thus, when validated protocols with internal negative controls are used, residual contamination minimally impacts statistical outcomes. IMPORTANCE: Microbiome studies in low-biomass environments face challenges due to contamination. However, even after implementing strict contamination prevention, control, and analysis measures, the impact of residual contamination on the validity of statistical outcomes in such studies remains a topic of ongoing discussion. Our analyses reveal that key drivers of microbiome study outcomes are group dissimilarity and the number of unique taxa, while contamination has minimal impact on statistical outcomes, primarily limited to the number of differentially abundant taxa detected. A common approach to contamination control involves removing taxa based on published contaminant lists. However, our analysis shows that these lists are highly inconsistent across studies, limiting reliability. Instead, our results support the use of internal negative controls as the most robust means of identifying and mitigating contamination. Collectively, data show that low-biomass microbiome studies have reduced power to detect differences between groups. However, when differences are observed, they are unlikely to be contamination-driven. By prioritizing validated protocols that prevent, assess, and eliminate contaminants through the use of internal negative controls, researchers can minimize the impact of contamination and improve the reliability of results.


  • Top Cited Papers
    Open Access

    Microbiota and kidney disease: the road ahead

    by Patricia P. Bloom, Wendy S. Garrett, Kristina L. Penniston, Mari-Karoliina H. Winkler, Stanley L. Hazen, Jose Agudelo, Mangesh Suryavanshi, Ahmed Babiker, Dylan Dodd, Michael A. Fischbach, et al.

    More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.


  • Open Access

    Metagenomic and phylogenetic analyses reveal gene-level selection constrained by bacterial phylogeny, surrounding oxalate metabolism in the gut microbiota

    by Sromona D. Mukherjee, Mangesh Suryavanshi, John Knight, Dirk Lange, Aaron W. Miller

    The gut microbiota is critical for neutralizing dietary toxins. Oxalate is a toxin commonly produced by plants to deter herbivory and is widely consumed in the human diet. Excess levels of systemic or urinary oxalate increase risk of multiple urologic and cardiometabolic diseases. The current study employed multiple amplicon-based and shotgun metagenomic methodologies, alongside comparative phylogenetic analyses, to interrogate evolutionary radiation surrounding microbial oxalate degradation within the human gut microbiome. In conservative genome-based estimates, over 30% of gut microbial species harbored at least one oxalate-handling gene, with the specific pathways used dependent on bacterial phylum. Co-occurrence analyses revealed interactions between specialist genes that can metabolize oxalate or its by-products, but not multi-functional genes that can act in more than one oxalate-related pathway. Specialization was rare at the genome level. Amplicon-based metagenomic sequencing of the oxalate-degrading gene, formyl-CoA transferase ( frc ), coupled with molecular clock phylogenetic analyses are indicative of rapid evolutionary divergence, constrained by phylum. This was corroborated by paired analyses of non-synonymous to synonymous substitutions (dN/dS ratios), which pointed toward neutral to positive selection. Sequence similarity network analyses of frc sequences suggest extensive horizontal gene transferring has occurred with the frc gene, which may have facilitated rapid divergence. The frc gene was primarily allocated to the Pseudomonodota phylum, particularly the Bradyrhizobium genus, which is a species capable of utilizing oxalate as a sole carbon and energy source. Collectively evidence provides strong support that, for oxalate metabolism, evolutionary selection occurs at the gene level, through horizontal gene transfer, rather than at the species level. IMPORTANCE: A critical function of the gut microbiota is to neutralize dietary toxins, such as oxalate, which is highly prevalent in plant-based foods and is not degraded by host enzymes. However, little is known about the co-evolutionary patterns of plant toxins and the mammalian gut microbiota, which are expected to exhibit features of an evolutionary arms race. In the current work, we present molecular evidence that microbial genes for oxalate degradation are highly prevalent in humans, potentially driven by extensive horizontal gene transfer events. Phylogenetic analyses reveal that oxalate-degrading genes are under a positive selection pressure and have historically undergone rapid diversification events, which has led to diverse ecological strategies for handling oxalate by gut bacteria. Collectively, data shed light on potential evolutionary relationships between the diet and the gut microbiota that occur relatively independently of the mammalian host.


  • Open Access

    Complex system modeling reveals oxalate homeostasis is driven by diverse oxalate-degrading bacteria

    by Sromona D Mukherjee, Carlos Batagello, Ava Adler, Jose Agudelo, Anna Zampini, Mangesh Suryavanshi, Andrew Nguyen, Terry Orr, Denise Dearing, Manoj Monga, et al.

    Decades of research have made clear that host-associated microbiomes touch all facets of health. However, effective therapies that target the microbiome have been elusive given its inherent complexity. Here, we experimentally examined diet-microbe-host interactions through a complex systems framework, centered on dietary oxalate. Using multiple, independent molecular, rodent, and in vitro experimental models, we found that microbiome composition influenced multiple oxalate-microbe-host interfaces. Importantly, the administration of the oxalate-degrading specialist, Oxalobacter formigenes, was only effective against a poor oxalate-degrading microbiota background and gives critical new insights into why clinical intervention trials with this species exhibit variable outcomes. Data suggest that, while heterogeneity in the microbiome impacts multiple diet-host-microbe interfaces, metabolic redundancy among diverse microorganisms in specific diet-microbe axes is a critical variable that may impact the efficacy of bacteriotherapies, which can help guide patient and probiotic selection criteria in probiotic clinical trials.